Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

BACKGROUND: Advanced biliary tract carcinoma has a very poor prognosis, with chemotherapy being the mainstay of treatment. Sorafenib, a multikinase inhibitor of VEGFR-2/-3, PDGFR-β, B-Raf, and C-Raf, has shown to be active in preclinical models of cholangiocarcinoma. METHODS: We conducted a phase II...

Descripción completa

Detalles Bibliográficos
Autores principales: Bengala, C, Bertolini, F, Malavasi, N, Boni, C, Aitini, E, Dealis, C, Zironi, S, Depenni, R, Fontana, A, Del Giovane, C, Luppi, G, Conte, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813746/
https://www.ncbi.nlm.nih.gov/pubmed/19935794
http://dx.doi.org/10.1038/sj.bjc.6605458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813746/
https://www.ncbi.nlm.nih.gov/pubmed/19935794
http://dx.doi.org/10.1038/sj.bjc.6605458

Ejemplares similares